New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
07:25 EDTPFE, AZN, GSKBerenberg feels Pfizer offer for Glaxo has some 'merits,' Reuters says
Analysts at Berenberg Bank feel that GlaxoSmithKline (GSK) could be too big for Pfizer (PFE) to deal with, but the acquisition could be a potential "plan B" after Pfizer failed to gain AstraZeneca (AZN), according to Reuters, citing comments from the analysts. The analysts said, "GSK may just be too large for Pfizer to handle, but as a plan B it has some merits." Reference Link
News For PFE;GSK;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 20, 2015
08:02 EDTPFEMerck KGaA, Pfizer initiate Phase III study with Avelumab
Subscribe for More Information
07:20 EDTGSKAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
07:01 EDTGSKPernix Therapeutics obtains six months U.S. pediatric exclusivity for Treximet
Subscribe for More Information
06:05 EDTPFEProvectus receives notice of allowance for PV-10 combined with other drugs
Subscribe for More Information
06:02 EDTAZNClovis pullback on Astra data a buying opportunity, says Mizuho
Subscribe for More Information
April 17, 2015
06:52 EDTAZNAstraZeneca granted FDA orphan drug designation for selumetinib
AstraZeneca announced that the FDA has granted orphan drug designation for the MEK inhibitor selumetinib, for the treatment of uveal melanoma, a rare disease in which cancer cells form in the tissues of the eye.
06:50 EDTAZNAstra reports median progression free survival of 13.5 months in AURA study
Subscribe for More Information
April 16, 2015
09:14 EDTGSKAdamis says albuterol HFA product study met clinical FEV1 primary endpoint
Subscribe for More Information
09:12 EDTAZNAstraZeneca granted orphan status for melanoma treatment
Subscribe for More Information
08:15 EDTGSKGlaxoSmithKline and Theravance announce launch of Anoro in Spain
In a regulatory filing, GlaxoSmithKline (GSK) and Theravance (THRX) announced the launch of Anoro in Spain following the approval in Europe in May 2014. Anoro Ellipta is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease. Anoro Ellipta is a combination of two bronchodilators, umeclidinium, a long-acting muscarinic antagonist and vilanterol, a long-acting beta2 agonist, in a single dry powder inhaler, the Ellipta. The approved dose of UMEC/VI is 55/22mcg. UMEC/VI has been developed under the 2002 LABA collaboration agreement between Glaxo Group Limited and Theravance.
07:58 EDTAZNAstraZeneca's MedImmune, Immunocore announce new collaboration agreement
Subscribe for More Information
April 15, 2015
11:53 EDTGSKGlaxoSmithKline initiated with a Sell at Societe Generale
11:50 EDTAZNAstraZeneca initiated with a Buy at Societe Generale
08:04 EDTPFEPfizer: PALOMA-3 trial for IBRANCE met primary endpoint, trial stopped early
Subscribe for More Information
07:41 EDTAZNEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
April 14, 2015
12:06 EDTAZNFDA panel accepts Onglyza's safety profile in 13-1 vote
Subscribe for More Information
07:15 EDTAZNFDA Endocrinologic & Metabolic Drugs Advisory Committee holds a meeting
Subscribe for More Information
April 13, 2015
15:12 EDTPFEMylan enters settlement, license agreement with Pfizer regarding Viagra
Mylan (MYL) announced that its subsidiaries Mylan Inc. and Mylan Pharmaceuticals have entered into a settlement and license agreement with Pfizer (PFE), Pfizer Limited and Pfizer Ireland Pharmaceuticals to settle patent litigation relating to Mylan's Abbreviated New Drug Application filed with the U.S. FDA for Sildenafil Citrate Tablets 25 mg, 50 mg, and 100 mg. This product is the generic version of Viagra, which is indicated to treat erectile dysfunction. Under the terms of the agreement, Mylan will be able to launch its ANDA products pursuant to a royalty-bearing license as early as December 11, 2017, or sooner under certain conditions, subject to FDA approval. All other terms and conditions of the settlement and license agreement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission. For the 12 months ending Dec. 31, 2014, Viagra had U.S. sales of approximately $1.3B, according to IMS Health.
08:58 EDTAZNMerck may have positive read through from briefing docs, says SunTrust
Subscribe for More Information
08:54 EDTAZNAstraZeneca has negative read through from briefing docs, says SunTrust
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use